NCT04797767 - Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 4, 2022

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions

Acute Biphenotypic LeukemiaAcute Myeloid LeukemiaMixed Phenotype Acute LeukemiaMyeloid NeoplasmRelapsed Acute Biphenotypic LeukemiaRelapsed Acute Myeloid LeukemiaRelapsed Mixed Phenotype Acute LeukemiaRelapsed Myeloid NeoplasmRefractory Acute Biphenotypic LeukemiaRefractory Acute Myeloid LeukemiaRefractory Mixed Phenotype Acute LeukemiaRefractory Myeloid NeoplasmRecurrent Myeloid Sarcoma

Interventions

DRUG

Cladribine

Given IV

DRUG

Cytarabine

Given IV

DRUG

Mitoxantrone

Given IV

BIOLOGICAL

Recombinant Granulocyte Colony-Stimulating Factor

Given subcutaneously

DRUG

Venetoclax

Given PO

PROCEDURE

Bone Marrow Aspiration

Undergo bone marrow aspiration

PROCEDURE

Bone Marrow Biopsy

Undergo bone marrow biopsy

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

Trial Locations (1)

98109

RECRUITING

Fred Hutch/University of Washington Cancer Consortium, Seattle